Target intelligence / Profile preview

Cannabinoid receptor 2 (CB2)

Target
CB2
Molecular classification
G protein-coupled receptor, Receptor
01

Overview

Cannabinoid receptor 2 (CB2), encoded by the CNR2 gene, is a class A G protein-coupled receptor (GPCR) that belongs to the endocannabinoid system. Unlike its counterpart CB1, which is predominantly expressed in the central nervous system, CB2 is primarily localized in peripheral tissues, particularly on immune cells such as B cells, T cells, macrophages, and microglia. It plays a critical role in modulating immune responses, inflammatory pathways, cell migration, and cytokine secretion. CB2 is highly inducible, with its expression levels dramatically increasing during tissue injury, inflammation, or neurodegenerative processes.\n\nConsequently, it has emerged as a promising therapeutic target for conditions such as neuropathic pain, chronic inflammation, autoimmune diseases, neurodegenerative disorders (e.g., Alzheimer's and Parkinson's diseases), and certain cancers. Pharmacological modulation of CB2 involves selective agonists (such as lenabasum and HU-308) and inverse agonists/antagonists (such as AM-630 and SR144528). A major therapeutic advantage of targeting CB2 over CB1 is the avoidance of the psychoactive and psychotropic side effects typically associated with CB1 activation. However, clinical translation has faced challenges, including species-specific differences in receptor binding, receptor desensitization, and maintaining high selectivity to prevent off-target CB1 activation.

Other names
CNR2CB-2CB2RCX5Cannabinoid receptor type 2
02

Mechanism of action

Agonism, antagonism, and inverse agonism of the receptor to modulate downstream G-protein signaling pathways.

03

Biological functions

Signal transductionImmune responseInflammatory responseSynaptic transmissionCell migrationCytokine secretion
04

Disease associations

InflammationPainNeurodegenerative diseaseAutoimmune diseaseCancerOsteoporosisCardiovascular diseaseInfection
05

Safety considerations

ImmunosuppressionLack of clinical efficacyOff-target effects on CB1 receptor leading to psychotropic side effectsSpecies differences in receptor binding and signalingReceptor desensitization and downregulation
06

Interacting drugs

11 more in the full profile.

07

Biomarkers

CB2 receptor expression levelsCNR2 gene expressionCB2 PET imagingLymphocyte CB2R expression

Beyond the preview

Go deeper on Cannabinoid receptor 2 (CB2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cannabinoid receptor 2 (CB2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call